INV-144
INV-144 is InVasc’s most advanced drug in development. INV-144 is a combination of losartan, a generic antihypertensive drug, in combination with alpha lipoic acid, a powerful antioxidant and Nrf2 activator. In a Phase II, "proof-of-concept" (POC) clinical trial, the QUALITY study, sponsored by InVasc to evaluate another antihypertensive inhibitor-nutraceutical combination, statistical significance was achieved for the primary endpoint of proteinuria and several other secondary endpoints. INV-144 is currently being tested in an 80 patient Phase IIa clinical trial. Results from this trial will be available in mid 2012.
There are more than 26 million patients in the U.S. with chronic kidney disease. The data from the QUALITY study suggests that INV-144 can slow the progression of the disease. At Stage V, kidney disease patients must undergo dialysis or a transplant, both life altering and costly alternatives.
InVasc has a pending ‘method-of-use’ patent that protects not only INV-144 but other similar compounds. The Company has also in-licensed a number of other issued and pending patents related to alpha lipoic acid synthesis, purification, formulation and usage. InVasc believes this combination of intellectual property will provide appropriate exclusivity in both the U.S. and Europe.
Proof of Concept demonstrated in a Phase II Clinical
